blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2496557

EP2496557 - TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.10.2014
Database last updated on 30.07.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
GlaxoSmithKline LLC
One Franklin Plaza
200 North 16th Street
Philadelphia, PA 19102 / US
[N/P]
Former [2012/37]For all designated states
GlaxoSmithKline LLC
One Franklin Plaza 200 North 16th Street
Philadelphia, PA 19102 / US
Inventor(s)01 / DEMONT, Emmanuel, Hubert
GlaxoSmithKline
Gunnels Wood Road
Stevenage Hertfordshire SG1 2NY / GB
02 / GARTON, Neil, Stuart
GlaxoSmithKline
Gunnels Wood Road
Stevenage Hertfordshire SG1 2NY / GB
03 / GOSMINI, Romain, Luc, Marie
c/o Laboratoire GlaxoSmithKline S.A.S.
Centre de Recherches
25 Avenue du Quebec
ZA de Courtaboeuf
F-91951 Les Ulis / FR
04 / HAYHOW, Thomas, George, Christopher
GlaxoSmithKline
Gunnels Wood Road
Stevenage Hertfordshire SG1 2NY / GB
05 / SEAL, Jonathan
GlaxoSmithKline
Gunnels Wood Road
Stevenage Hertfordshire SG1 2NY / GB
06 / WILSON, David, Matthew
GlaxoSmithKline
Gunnels Wood Road
Stevenage Hertfordshire SG1 2NY / GB
07 / WOODROW, Michael, David
GlaxoSmithKline
Gunnels Wood Road
Stevenage Hertfordshire SG1 2NY / GB
 [2012/37]
Representative(s)Shore, Andrew David
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
[N/P]
Former [2012/37]Shore, Andrew David
GlaxoSmithKline Corporate Intellectual Property (CN 925.1) 980 Great West Road Brentford
Middlesex TW8 9GS / GB
Application number, filing date10773324.803.11.2010
WO2010EP66693
Priority number, dateGB2009001943105.11.2009         Original published format: GB 0919431
[2012/37]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011054841
Date:12.05.2011
Language:EN
[2011/19]
Type: A1 Application with search report 
No.:EP2496557
Date:12.09.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 12.05.2011 takes the place of the publication of the European patent application.
[2012/37]
Type: B1 Patent specification 
No.:EP2496557
Date:18.12.2013
Language:EN
[2013/51]
Search report(s)International search report - published on:EP12.05.2011
ClassificationIPC:C07D215/42, C07D413/04, C07D401/04, A61K31/4706, A61P35/00
[2012/37]
CPC:
C07D215/42 (EP,US); A61P29/00 (EP); A61P35/00 (EP);
A61P37/00 (EP); A61P37/02 (EP); A61P43/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/37]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:TETRAHYDROQUINOLINE DERIVATE UND IHRE PHARMAZEUTISCHE ANWENDUNG[2013/10]
English:TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE[2012/37]
French:DERIVES DE TETRAHYDROQUINOLINE ET LEUR UTILISATION PHARMACEUTIQUE[2013/10]
Former [2012/37]TETRAHYDROCHINOLINDERIVATE UND IHRE PHARMAZEUTISCHE VERWENDUNG
Former [2012/37]DÉRIVÉS DE TÉTRAHYDROQUINOLINE ET LEUR UTILISATION PHARMACEUTIQUE
Entry into regional phase27.04.2012National basic fee paid 
27.04.2012Designation fee(s) paid 
27.04.2012Examination fee paid 
Examination procedure27.04.2012Amendment by applicant (claims and/or description)
27.04.2012Examination requested  [2012/37]
13.02.2013Despatch of a communication from the examining division (Time limit: M04)
03.06.2013Reply to a communication from the examining division
25.06.2013Communication of intention to grant the patent
11.10.2013Fee for grant paid
11.10.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.02.2013
Opposition(s)19.09.2014No opposition filed within time limit [2014/48]
Fees paidRenewal fee
07.11.2012Renewal fee patent year 03
07.11.2013Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.11.2010
AL18.12.2013
AT18.12.2013
BE18.12.2013
BG18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
MK18.12.2013
MT18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
RS18.12.2013
SE18.12.2013
SI18.12.2013
SK18.12.2013
SM18.12.2013
TR18.12.2013
NO18.03.2014
GR19.03.2014
IS18.04.2014
PT18.04.2014
[2018/46]
Former [2018/30]HU03.11.2010
AT18.12.2013
BE18.12.2013
BG18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
MK18.12.2013
MT18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
RS18.12.2013
SE18.12.2013
SI18.12.2013
SK18.12.2013
SM18.12.2013
TR18.12.2013
NO18.03.2014
GR19.03.2014
IS18.04.2014
PT18.04.2014
Former [2016/33]HU03.11.2010
AT18.12.2013
BE18.12.2013
BG18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
MT18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
RS18.12.2013
SE18.12.2013
SI18.12.2013
SK18.12.2013
SM18.12.2013
TR18.12.2013
NO18.03.2014
GR19.03.2014
IS18.04.2014
PT18.04.2014
Former [2016/32]HU03.11.2010
AT18.12.2013
BE18.12.2013
BG18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
RS18.12.2013
SE18.12.2013
SI18.12.2013
SK18.12.2013
SM18.12.2013
TR18.12.2013
NO18.03.2014
GR19.03.2014
IS18.04.2014
PT18.04.2014
Former [2016/28]AT18.12.2013
BE18.12.2013
BG18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
RS18.12.2013
SE18.12.2013
SI18.12.2013
SK18.12.2013
SM18.12.2013
NO18.03.2014
GR19.03.2014
IS18.04.2014
PT18.04.2014
Former [2016/22]AT18.12.2013
BE18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
RS18.12.2013
SE18.12.2013
SI18.12.2013
SK18.12.2013
SM18.12.2013
NO18.03.2014
IS18.04.2014
PT18.04.2014
Former [2015/32]AT18.12.2013
BE18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
MC18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
RS18.12.2013
SE18.12.2013
SI18.12.2013
SK18.12.2013
NO18.03.2014
IS18.04.2014
PT18.04.2014
Former [2015/24]AT18.12.2013
BE18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
RS18.12.2013
SE18.12.2013
SI18.12.2013
SK18.12.2013
NO18.03.2014
IS18.04.2014
PT18.04.2014
Former [2014/48]AT18.12.2013
BE18.12.2013
CY18.12.2013
CZ18.12.2013
DK18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
RS18.12.2013
SE18.12.2013
SK18.12.2013
NO18.03.2014
IS18.04.2014
PT18.04.2014
Former [2014/39]AT18.12.2013
BE18.12.2013
CY18.12.2013
CZ18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
NL18.12.2013
PL18.12.2013
RO18.12.2013
RS18.12.2013
SE18.12.2013
SK18.12.2013
NO18.03.2014
IS18.04.2014
PT18.04.2014
Former [2014/37]AT18.12.2013
BE18.12.2013
CY18.12.2013
CZ18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
PL18.12.2013
RO18.12.2013
RS18.12.2013
SE18.12.2013
SK18.12.2013
NO18.03.2014
IS18.04.2014
PT18.04.2014
Former [2014/36]BE18.12.2013
EE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
RS18.12.2013
SE18.12.2013
NO18.03.2014
IS18.04.2014
Former [2014/34]BE18.12.2013
FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
RS18.12.2013
SE18.12.2013
NO18.03.2014
Former [2014/25]FI18.12.2013
HR18.12.2013
LT18.12.2013
LV18.12.2013
RS18.12.2013
SE18.12.2013
NO18.03.2014
Former [2014/24]FI18.12.2013
HR18.12.2013
LT18.12.2013
RS18.12.2013
SE18.12.2013
NO18.03.2014
Former [2014/23]FI18.12.2013
HR18.12.2013
LT18.12.2013
SE18.12.2013
NO18.03.2014
Former [2014/22]FI18.12.2013
LT18.12.2013
SE18.12.2013
NO18.03.2014
Former [2014/20]LT18.12.2013
NO18.03.2014
Cited inInternational search[A]EP0987251  (PFIZER PROD INC [US]) [A] 1-26 * pages 2-4 *;
 [AD]WO2009084693  (MITSUBISHI TANABE PHARMA CORP [JP], et al) [AD] 1-26;
 EP2239264  [ ] (MITSUBISHI TANABE PHARMA CORP [JP]) [ ] * pages 2-3 *;
 [A]  - F. MANZO ET AL., "Histone acetyltransferase inhibitors and preclinical studies", EXPERT OPIN. THER. PATENTS, (200906), vol. 19, no. 6, pages 761 - 774, XP002616149 [A] 1-26 * figure 2c *

DOI:   http://dx.doi.org/10.1517/13543770902895727
by applicantJP2008156311
 WO2009084693
 GB2242134
 WO2005044354
 EP0123456
 WO2005100321
    - LEROY ET AL., MOL. CELL, (2008), vol. 30, no. 1, pages 51 - 60
    - HARGREAVES ET AL., CELL, (2009), vol. 138, no. 1, pages 129 - 145
    - FRENCH ET AL., CANCER RESEARCH, (2003), vol. 63, pages 304 - 307
    - FRENCH ET AL., JOURNAL OF CLINICAL ONCOLOGY, (2004), vol. 22, no. 20, pages 4135 - 4139
    - ONCOGENE, (2008), vol. 27, pages 2237 - 2242
    - YOU ET AL., CELL, (2004), vol. 117, no. 3, pages 349 - 60
    - BERGE ET AL., J. PHARM. SCI., (1977), vol. 66, pages 1 - 19
    - Burger's Medicinal Chemistry and Drug Discovery, vol. 1
    - EUR. J. ORG. CHEM., (2004), pages 959 - 964
    - INT. J. PEPTIDE PROTEIN RES., (1992), vol. 40, pages 13 - 18
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.